Literature DB >> 23748471

Development and characterization of a reliable mouse model of colorectal cancer metastasis to the liver.

Yu Zhang1, Celestia Davis, James Ryan, Cory Janney, Maria Marjorette O Peña.   

Abstract

Colorectal cancer (CRC) is the third most frequent cancer and the third leading cause of cancer deaths in the United States (American Cancer Society, Cancer facts and figures 2012, 20121). The major cause of death is metastasis and frequently, the target organ is the liver. Successful metastasis depends on acquired properties in cancer cells that promote invasion and migration, and on multiple interactions between tumors and host-derived cells in the microenvironment. These processes, however, occur asymptomatically, thus, metastasis remains poorly understood and often diagnosed only at the final stage. To facilitate the elucidation of the mechanisms underlying these processes and to identify the molecular regulators, particularly at the early stages, we developed a mouse model of hepatic metastasis of CRC by cecal implantation of a mouse adenocarcinoma cell line in an immune competent host that reliably recapitulates all steps of tumor growth and metastasis within a defined period. By in vivo selection, we isolated cells of varying metastatic potential. The most highly metastatic CT26-FL3 cells produced liver metastasis as early as 10 days after implantation in 90 % of host mice. These cells expressed elevated levels of genes whose products promote invasion, migration, and mobilization of bone marrow derived cells (BMDCs). Mice bearing tumors from CT26-FL3 had elevated serum levels of OPN, MMP9, S100A8, S100A9, SAA3, and VEGFA that promote invasion and BMDC mobilization, and showed enhanced BMDC recruitment to the liver where they established a pre-metastatic niche. This model provides an important platform to characterize metastatic cells and elucidate tumor-host interactions and mechanisms that drive liver metastasis of CRC.

Entities:  

Mesh:

Year:  2013        PMID: 23748471      PMCID: PMC3836876          DOI: 10.1007/s10585-013-9591-8

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  62 in total

Review 1.  Matrix metalloproteinases and tumor metastasis.

Authors:  Elena I Deryugina; James P Quigley
Journal:  Cancer Metastasis Rev       Date:  2006-03       Impact factor: 9.264

2.  Fourier analysis of cell motility: correlation of motility with metastatic potential.

Authors:  A W Partin; J S Schoeniger; J L Mohler; D S Coffey
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

Review 3.  The two faces of interferon-γ in cancer.

Authors:  M Raza Zaidi; Glenn Merlino
Journal:  Clin Cancer Res       Date:  2011-06-24       Impact factor: 12.531

4.  The interferon (IFN)-induced GTPase, mGBP-2. Role in IFN-gamma-induced murine fibroblast proliferation.

Authors:  Victoria Y Gorbacheva; Daniel Lindner; Ganes C Sen; Deborah J Vestal
Journal:  J Biol Chem       Date:  2001-11-28       Impact factor: 5.157

Review 5.  Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage.

Authors:  Sergei I Grivennikov; Michael Karin
Journal:  Ann Rheum Dis       Date:  2011-03       Impact factor: 19.103

6.  Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer.

Authors:  Yasuhide Yamada; Tatsuro Yamaguchi; Hiroshi Matsumoto; Yasushi Ichikawa; Ayumu Goto; Ken Kato; Tetsuya Hamaguchi; Yasuhiro Shimada
Journal:  Invest New Drugs       Date:  2011-09-06       Impact factor: 3.850

7.  IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer.

Authors:  Sergei Grivennikov; Eliad Karin; Janos Terzic; Daniel Mucida; Guann-Yi Yu; Sivakumar Vallabhapurapu; Jürgen Scheller; Stefan Rose-John; Hilde Cheroutre; Lars Eckmann; Michael Karin
Journal:  Cancer Cell       Date:  2009-02-03       Impact factor: 31.743

8.  Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis.

Authors:  Boryana K Popivanova; Kazuya Kitamura; Yu Wu; Toshikazu Kondo; Takashi Kagaya; Shiuchi Kaneko; Masanobu Oshima; Chifumi Fujii; Naofumi Mukaida
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

9.  CXCL1/macrophage inflammatory protein-2-induced angiogenesis in vivo is mediated by neutrophil-derived vascular endothelial growth factor-A.

Authors:  Patrizia Scapini; Monica Morini; Cristina Tecchio; Simona Minghelli; Emma Di Carlo; Elena Tanghetti; Adriana Albini; Clifford Lowell; Giorgio Berton; Douglas M Noonan; Marco A Cassatella
Journal:  J Immunol       Date:  2004-04-15       Impact factor: 5.422

Review 10.  Preparing the "soil": the premetastatic niche.

Authors:  Rosandra N Kaplan; Shahin Rafii; David Lyden
Journal:  Cancer Res       Date:  2006-12-01       Impact factor: 12.701

View more
  29 in total

1.  Six1 promotes colorectal cancer growth and metastasis by stimulating angiogenesis and recruiting tumor-associated macrophages.

Authors:  Hanwen Xu; Yu Zhang; Maria M Peña; Lucia Pirisi; Kim E Creek
Journal:  Carcinogenesis       Date:  2017-03-01       Impact factor: 4.944

2.  Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy.

Authors:  Keehoon Jung; Takahiro Heishi; Omar F Khan; Piotr S Kowalski; Joao Incio; Nuh N Rahbari; Euiheon Chung; Jeffrey W Clark; Christopher G Willett; Andrew D Luster; Seok Hyun Yun; Robert Langer; Daniel G Anderson; Timothy P Padera; Rakesh K Jain; Dai Fukumura
Journal:  J Clin Invest       Date:  2017-07-10       Impact factor: 14.808

3.  Tissue inhibitor of metalloproteinases (TIMP)-1 creates a premetastatic niche in the liver through SDF-1/CXCR4-dependent neutrophil recruitment in mice.

Authors:  Bastian Seubert; Barbara Grünwald; Julia Kobuch; Haissi Cui; Florian Schelter; Susanne Schaten; Jens T Siveke; Ngee H Lim; Hideaki Nagase; Nicole Simonavicius; Mathias Heikenwalder; Thomas Reinheckel; Jonathan P Sleeman; Klaus-Peter Janssen; Percy A Knolle; Achim Krüger
Journal:  Hepatology       Date:  2014-11-24       Impact factor: 17.425

4.  Local and transient gene expression primes the liver to resist cancer metastasis.

Authors:  Tyler J Goodwin; Yingqiu Zhou; Sara N Musetti; Rihe Liu; Leaf Huang
Journal:  Sci Transl Med       Date:  2016-11-09       Impact factor: 17.956

5.  Enhanced colorectal cancer metastases in the alcohol-injured liver.

Authors:  Ashley M Mohr; John J Gould; Jacy L Kubik; Geoffrey A Talmon; Carol A Casey; Peter Thomas; Dean J Tuma; Benita L McVicker
Journal:  Clin Exp Metastasis       Date:  2017-02-06       Impact factor: 5.150

6.  Investigation of phosphorylated adjuvants co-encapsulated with a model cancer peptide antigen for the treatment of colorectal cancer and liver metastasis.

Authors:  Tyler J Goodwin; Leaf Huang
Journal:  Vaccine       Date:  2017-04-03       Impact factor: 3.641

7.  IL-33 promotes growth and liver metastasis of colorectal cancer in mice by remodeling the tumor microenvironment and inducing angiogenesis.

Authors:  Yu Zhang; Celestia Davis; Sapana Shah; Daniel Hughes; James C Ryan; Diego Altomare; Maria Marjorette O Peña
Journal:  Mol Carcinog       Date:  2016-04-27       Impact factor: 4.784

Review 8.  Premetastatic niche formation in the liver: emerging mechanisms and mouse models.

Authors:  Achim Krüger
Journal:  J Mol Med (Berl)       Date:  2015-09-24       Impact factor: 4.599

Review 9.  Animal models of gastrointestinal and liver diseases. New mouse models for studying dietary prevention of colorectal cancer.

Authors:  James C Fleet
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-05-29       Impact factor: 4.052

Review 10.  Hepatic metastatic niche: from normal to pre-metastatic and metastatic niche.

Authors:  Shirin Azizidoost; Ahmad Ahmadzadeh; Fakher Rahim; Mohammad Shahjahani; Mohammad Seghatoleslami; Najmaldin Saki
Journal:  Tumour Biol       Date:  2015-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.